RxDoctor Payments DataLook up a doctor →

Ann Henderson

Nurse Practitioner · Columbia, MDNPI 1720054620

Payments from drug & device makers

$14,149in general payments, 2019–2025

Across 541 payments — averaging $26.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Novartis$1K
  • AstraZeneca$871
  • Daiichi Sankyo Inc.$634
  • Merck$628
  • AbbVie$542
  • plus $9K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)51$1,351
Novartis50$1,101
AstraZeneca(2 entities)24$871
Daiichi Sankyo Inc.29$634
Merck35$628
AbbVie17$542
Seagen Inc.24$522
Pfizer22$409
E.r. Squibb & Sons, L.L.C.11$404
Eisai Inc.23$389
Puma Biotechnology, Inc.12$349
Takeda Pharmaceuticals U.S.A., Inc.12$328
Rigel Pharmaceuticals, Inc.11$327
Genentech USA, Inc.15$303
GSK11$283
Lilly USA, LLC10$266
Incyte Corporation10$256
Bristol Myers Squibb12$241
Sanofi9$240
Regeneron Healthcare Solutions, Inc.10$231
AVEO Pharmaceuticals, Inc.6$221
Sobi, Inc6$220
Bayer10$216
Pharmacyclics LLC, An Abbvie Company9$214
Exelixis Inc.8$175
Sage Therapeutics, LLC2$174
Pharmaessentia USA Corporation7$171
Boehringer Ingelheim2$137
Ipsen Biopharmaceuticals, Inc5$128
ADC Therapeutics America, Inc.5$126
Beigene USA, Inc.4$124
Mirati Therapeutics, Inc.4$124
ARS Pharmaceuticals Operations, Inc.1$122
Gilead(2 entities)5$120
Alkermes, Inc.1$120
Teva Pharmaceuticals USA, Inc.1$120
Taiho Oncology, Inc.5$119
Coloplast1$112
Amgen1$110
Global Blood Therapeutics, Inc.5$109
Neurocrine Biosciences, Inc.1$108
Morphosys, US Inc.5$105
Axsome Therapeutics, Inc.1$105
Idorsia Pharmaceuticals US Inc1$101
Sanofi-aventis U.S. LLC1$96
Insmed, Inc.1$93
Astellas Pharma US Inc5$90
Recordati_rare_diseases_inc.2$71
Genmab U.S., Inc.2$68
Karyopharm Therapeutics Inc.3$67
Kyowa Kirin, Inc.3$62
Stemline Therapeutics Inc.3$60
Array Biopharma Inc4$58
Immunogen, Inc.2$54
Servier Pharmaceuticals LLC3$45
Epizyme, Inc.2$42
Alnylam Pharmaceuticals Inc.3$38
Myriad Genetic Laboratories, Inc.2$35
Shield Therapeutics Inc1$28
Janssen Scientific Affairs, LLC1$23

How this compares

$14,149 in reported general payments places this provider in the 95th percentile of 1,562 nurse practitioner providers in Maryland.

See all nurse practitioner providers in Maryland →

Medicare billing

Part B allowed, 2024
$14,335
Medicare patients
139
Services billed
168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nurse practitioner in Columbia

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →